ELDN

Eledon Pharmaceuticals, Inc. (ELDN) - Q3 2025 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended September 30, 2025. Eledon Pharmaceuticals is a clinical-stage biotechnology company focused on developing tegoprubart, an anti-CD40L antibody, for the prevention of organ transplant rejection (kidney and islet cell) and the treatment of amyotrophic lateral sclerosis (ALS). The company operates as a single segment and has no approved products for commercial sale.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss vs. Net Income: The company reported a net loss of $17.5 million for Q3 2025, compared to a net income of $77.0 million in Q3 2024. The prior year's income was driven by a $96.4 million gain from the change in fair value of warrant liabilities (due to the expiration of certain warrants), whereas Q3 2025 saw only a $0.6 million gain in this category.
• Operating Expenses: Total operating expenses decreased slightly by $1.4 million in Q3 2025 compared to Q3 2024. However, on a year-to-date basis, expenses increased by $15.9 million, primarily due to higher R&D costs ($14.7 million increase) driven by increased clinical trial activities (Phase 1b, Phase 2 BESTOW) and manufacturing.
• Liquidity: Cash and cash equivalents decreased from $20.5 million at year-end 2024 to $3.7 million at Q3 2025, though total liquid assets (including short-term investments) remain at $93.4 million.
• Restatement: The company restated prior period financial statements to reclassify Series X and Series X1 preferred stock from permanent equity to temporary equity and to apply the two-class method for earnings per share calculations.

Guidance, Outlook, and Risks

• Clinical Progress:
  • Kidney Transplant: Topline data from the Phase 2 BESTOW trial (announced Nov 6, 2025) showed tegoprubart maintained strong renal function (eGFR ~69 mL/min/1.73 m²) with a favorable safety profile compared to tacrolimus, including significantly lower rates of new-onset diabetes and tremor. The efficacy failure composite endpoint demonstrated non-inferiority.
  • Islet Cell Transplant: Positive data reported for an investigator-initiated trial showing insulin independence in recipients.
  • ALS: The company stated it cannot continue clinical development for ALS without additional financing.
• Capital Requirements: Management expects to incur net losses for the foreseeable future. While current resources are sufficient for at least 12 months, additional funding is required to complete development of tegoprubart, particularly for the ALS program.
• Recent Financing (Subsequent Event): On November 12, 2025, the company closed an underwritten offering raising approximately $53.6 million in net proceeds.
• Risks:
  • Internal Controls: A material weakness in internal control over financial reporting remains unremediated, leading to ineffective disclosure controls.
  • Liquidity Risk: Dependence on future equity or debt financing to continue operations.
  • Development Risk: Clinical trials may fail to demonstrate efficacy or safety in later stages.

Investor Verification Checklist

• Verify the impact of the material weakness in internal controls on the reliability of future financial reporting.
• Confirm the timeline and funding requirements for the ALS program, which management explicitly stated requires additional financing to continue.
• Review the details of the November 2025 underwritten offering ($53.6M net proceeds) to assess dilution and runway extension.
• Monitor the change in fair value of warrant liabilities, which significantly impacts net income/loss volatility.
• Assess the non-inferiority margin and statistical significance of the Phase 2 BESTOW trial results regarding the primary endpoint (eGFR) versus the composite efficacy failure endpoint.